Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Vivek Naranbhai,Alejandro B. Balazs +17 more
Reads0
Chats0
TLDR
In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.About:
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 1109 citations till now. The article focuses on the topics: Vaccination & Humoral immunity.read more
Citations
More filters
Journal ArticleDOI
Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design
TL;DR: In this paper , the authors proposed an open-source multi-criteria decision-making platform, which provides a scientific approach to selecting epitopes with appropriate conservity and immunogenicity; against everchanging viruses.
Journal ArticleDOI
VGsim: Scalable viral genealogy simulator for global pandemic
Vladimir Shchur,Vadim Spirin,D. S. Sirotkin,Evgeni Burovski,Nicola De Maio,Russell Corbett-Detig +5 more
TL;DR: A new fast simulator VGsim is introduced which addresses the problem of simulation genealogies under epidemiological models and can model complex population structure, epistasis and immunity escape.
Journal ArticleDOI
Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro
TL;DR: In this article , polymannuronate monophosphate (PMPD) was shown to be the most effective component to block the interaction of spike to ACE2 with an IC50 of 85.5 nM.
Journal ArticleDOI
Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies
Jiahui Chen,Guoshen Wei +1 more
TL;DR: It is demonstrated that topological AI-designed mAbs are effective to variants of concerns and variants of interest designated by the World Health Organization (WHO), as well as the original SARS-CoV-2.
Journal ArticleDOI
Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants
TL;DR: A review of state-of-the-art vaccine strategies involved in controlling the transmission of SARS-CoV-2 and its variants is presented in this paper , where challenges and future directions for rational vaccine design are discussed.
References
More filters
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more
TL;DR: A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic, and it is found that the G614 variant grows to higher titer as pseudotyped virions.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nina Le Bert,Anthony T. Tan,Kamini Kunasegaran,Christine Y.L. Tham,Morteza Hafezi,Adeline Chia,Melissa Hui Yen Chng,Meiyin Lin,Meiyin Lin,Nicole Tan,Martin Linster,Wan Ni Chia,Mark I-Cheng Chen,Lin-Fa Wang,Eng Eong Ooi,Shirin Kalimuddin,Paul A. Tambyah,Jenny G. Low,Jenny G. Low,Yee-Joo Tan,Yee-Joo Tan,Antonio Bertoletti,Antonio Bertoletti +22 more
TL;DR: Infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein, and SARS-CoV-2-reactive T cells were found in individuals who had recovered from SARS or COVID-19 and in unexposed donors, although with different patterns of immunoreactivity.
Related Papers (5)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Nicholas G Davies,Sam Abbott,Rosanna C. Barnard,Christopher I Jarvis,Adam J. Kucharski,James D Munday,Carl A. B. Pearson,Timothy W Russell,Damien C. Tully,Alex D. Washburne,Tom Wenseleers,Amy Gimma,William Waites,Kerry L. M. Wong,Kevin van Zandvoort,Justin D. Silverman,Karla Diaz-Ordaz,Ruth H. Keogh,Rosalind M Eggo,Sebastian Funk,Mark Jit,Katherine E. Atkins,Katherine E. Atkins,W. John Edmunds +23 more
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more